Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leuprolide Acetate Extension in Children with Central Precocious Puberty
NCT00667446Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Dec 2008
- Primary completion
- Oct 2012
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label trial of leuprolide in central precocious puberty (CPP) (2 arms), sponsored by AbbVie Inc. Primary endpoint: Percentage of Participants With Suppression of Peak-Stimulated Luteinizing Hormone at Month 36. Started Dec 2008; status: completed.
02
Drugs
leuprolide
03
Conditions
central precocious puberty (CPP)
Beyond the preview
Go deeper on NCT00667446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00667446.